Oncimmune Holdings PLC PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR (6216Q)
November 30 2016 - 12:47PM
UK Regulatory
TIDMONC
RNS Number : 6216Q
Oncimmune Holdings PLC
30 November 2016
30 November 2016
Oncimmune Holdings plc
("Oncimmune" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer
detection company developing and commercialising its proprietary
EarlyCDT(R) platform technology, today announces that on 30
November 2016, options over ordinary shares of 1 pence each in the
capital of the Company ("Ordinary Shares") were awarded to Dan
Calvo, President of Oncimmune (USA) LLC, a PDMR, as well as to
certain other US staff, under the Company's Oncimmune Holdings Plc
Incentive Stock Option Plan (as amended from the Oncimmune Limited
Incentive Stock Option Plan that became effective 27 July 2009) as
follows:
Name Position Number of Option Interest
share options exercise in issued
awarded price per share capital
share (pence) (%)
----------- ------------------ --------------- --------------- ---------------
President of
Oncimmune (USA)
Dan Calvo LLC 10,151 118.5 0.02
----------- ------------------ --------------- --------------- ---------------
The options are subject to the rules of the Incentive Stock
Option Plan and vest in five equal annual parts, the first fifth
vesting on 29 November 2017 and each year thereafter for a further
four years, subject to continued employment. The options are
exercisable at 118.5 pence, being the mid-market closing price of
the Ordinary Shares on 29 November 2016
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey
Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
1 Details of the person discharging managerial responsibilities/person closely associated
---- ----------------------------------------------------------------------------------------------------------------
a) Name Dan Calvo
---- ------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------------------------------------
President of Oncimmune (USA) LLC
a) Position/status
---- ------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial Notification
---- ------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------------------------------------------------------------
a) Name Oncimmune Holdings plc
---- ------------------------------------------------------- -------------------------------------------------------
b) LEI N/A
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of options over Ordinary Shares - Oncimmune Holdings Plc
instrument Incentive Stock Option Plan
Identification code
ISIN GB00BYQ94H38
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Grant of options over Ordinary Shares
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
N/A 10,151
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information Price(s) Volume(s)
---------- ----------
N/A 10,151
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 30 November 2016
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction N/A
---- ------------------------------------------------------- -------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHURSBRNNAAOAA
(END) Dow Jones Newswires
November 30, 2016 12:47 ET (17:47 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024
